| Deferiprone | Deferoxamine | p |
---|---|---|---|
No. Patients randomized | 28 | 32 | Â |
Age | 25.1 ± 3.8 | 26.6 ± 4.7 | 0.33 |
Male sex (%) | 15 (52) | 16 (50) | 0.99 |
Weight (kg) | 57.7 ± 7.9 | 60.6 ± 13.2 | 0.30 |
Cardiac parameters | Â | Â | Â |
Myocardial T2* (ms) | 13.0 (32%) | 13.3 (30%) | 0.77 |
LVEDV (mL) | 134 ± 32 | 132 ± 23 | 0.81 |
LVESV (mL) | 43 ± 14 | 41 ± 13 | 0.51 |
LVEF (%) | 69.7 ± 5.4 | 68.4 ± 4.9 | 0.34 |
RVEDV (mL) | 122.5 ± 24.9 | 124.7 ± 27.7 | 0.75 |
RVESV (mL) | 37.7 ± 11.7 | 38.1 ± 12.6 | 0.90 |
RVEF (%) | 69.6 ± 5.2 | 70.0 ± 5.8 | 0.79 |
Biochemical markers | Â | Â | Â |
Liver iron concentration (μg/L) | 6.16 ± 6.0 | 6.32 ± 5.8 | 0.92 |
Serum ferritin (μg/L) | 1791 ± 1029 | 2795 ± 2441 | 0.039 |
Haematology | Â | Â | Â |
Transfusional iron (mL/kg/year) | 152 ± 43.4 | 144 ± 44.4 | 0.53 |
Haemoglobin level (g/L) | 105 ± 12.0 | 113 ± 11.9 | 0.023 |